Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 25, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 580,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,467.9212 pence per share.
- Treasury Holdings: Following the purchase, the Company holds 290,122,678 shares in Treasury.
- Shares in Issue: 5,727,902,552 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 580,000 shares on April 25, 2007. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6. No specific risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the total number of shares in issue (5,727,902,552) for calculating ownership thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (290,122,678) for accurate fully diluted share count calculations.
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.